Stay updated on Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.

Latest updates to the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a Locations section listing participating sites by state (Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Utah) and included a Revision: v3.3.3 tag. Removed the previous HHS Vulnerability Disclosure entry and older state location entries (v3.3.2).SummaryDifference1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedNew revision tag v3.3.2 added with recent dates (e.g., 2025-11-21 and 2025-11-24), replacing the previous revision v3.3.1.SummaryDifference0.1%

- Check42 days agoChange DetectedMinor revision update from v3.2.0 to v3.3.1 with no visible changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedThe funding-status notice at the top of the ClinicalTrials.gov page has been removed; no trial details, eligibility criteria, or outcomes appear affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedNo significant changes detected between the two screenshots; core study details and contacts remain the same.SummaryDifference0.2%

- Check89 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference1%

Stay in the know with updates to Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.